Skip to main content
. 2022 Mar 12;306(1):267–275. doi: 10.1007/s00404-022-06453-z

Table 2.

CFAS National Membership Survey Results for the Top 5 Items

Item Sum of very important and moderately important responses Issue prevalence* Cost* Potential for harm* Aggregate score (%) of issue prevalence, cost, and potential for harm Recommended to include in Top 5 List*
1. PGT 54 (69.2) 28 (50.91) 55 (94.83) 42 (73.68) 73.1 40 (69.0)
2. High dose gonadotropins 49 (64.5) 39 (70.91) 42 (76.36) 37 (67.27) 71.5 30 (53.6)
3. Assisted hatching 49 (62.8) 34 (59.65 37 (66.07) 33 (58.93) 61.6 29 (51.8)
4. Immune therapy 52 (67.5) 17 (30.36) 43 (78.18) 43 (75.44) 61.3 37 (66.1)
5. DNA fragmentation 54 (68.4) 30 (54.55) 46 (85.19) 13 (24.07) 54.6 31 (54.4)

*Expressed as n (%) of respondents who answered “Yes,” in a yes or no question about whether the issue is prevalent, costly, has potential for harm, or should be in the top 5 list; note that respondents were able to skip questions